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Abstract: Diabetes mellitus is one of the major non-communicable diseases (NCD) with increasing
prevalence in China. There is a lack of high-quality research focusing on prevention and management
of diabetes in low and middle income countries (LMICs) compared to developed countries. This
comparative study aims to describe the characteristics of diabetes research conducted in China and
the USA. The study included 800 studies on diabetes mellitus from both countries. Compared with
studies in the USA, studies in China were more likely to be laboratory-based primary research (50.5%
versus 30.8%), more likely to use animal subjects (47% versus 27.5%), more likely to focused on risk
factors (22.7% versus. 14.7%), more likely to be case-controlled studies (17.7% versus 10.0%), and
more likely to evaluate pharmacological treatments (36.5% versus 20.7%). Further, compared with
studies in the USA, studies in China were less likely to involve patients (42.7% versus 60.7%), less
likely to be clinical trials (6.2% versus 14.5%), less likely to be cohort studies (8.8% versus. 26.0%),
and less likely to evaluate disease management interventions (3.3% versus 13.3%). Clinical studies in
China should be more patient-based to facilitate more effective control and management of diabetes.
Keywords: non-communicable disease; diabetes mellitus; comparative study; China; USA
1. Introduction
The burden of non-communicable diseases (NCDs) is rapidly increasing in low and middle income
countries (LMICs). NCDs are already the main causes of deaths and disabilities globally [1]. The
United Nations has recommended a shift in healthcare priority from infectious diseases to NCDs [2].
Clinical and public health decision-making needs to be informed by research regarding the burden of
NCDs, risk factors, genetic variation, influence of socio-economic changes, effects of interventions,
health system changes required, and implementation of the research in practice [3].
Studies on NCDs from LMICs is limited [4–6] and of poorer quality than those conducted in
developed countries [7]. For example, a bibliometric analysis of diabetes research in India showed
that research was focused more on epidemiology and less on prevention strategies or therapeutic
interventions [8].
Diabetes mellitus is one of the major NCDs with high and increasing prevalence in China [9]. The
prevalence of diabetes in China has increased substantially from 0.9% in 1980 to 11.6% in 2010 [10]. In
2016, the total number of people with diabetes in China reached 100 million and is growing steadily [11].
China is currently home to the largest number of people with diabetes in the world. Poor management
of diabetes has also led to higher death rates in China [12]. In the United States of America (USA),
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despite a decrease in the prevalence of diabetes, there are thought to be around 30.3 million people
with diabetes, and 84.1 million with a pre-diabetic condition [13]. Therefore, diabetes mellitus remains
a major public health problem in both China and the USA, imposing considerable health and economic
burdens on individuals and society [14,15].
There is lack of comparative research on NCDs in general, and on diabetes mellitus in particular,
across developed and developing countries. This study aims to compare the main characteristics of
research studies on diabetes conducted in China and the USA. The study aims to understand the
similarities and differences in research designs, types, and themes in respect of diabetes in China and
USA, and to provide empirical evidence reflecting public health research policies and priorities in
China and the USA.
2. Methods
2.1. Inclusion and Exclusion Criteria
Eligible studies met the following inclusion criteria:
• Primary research studies or secondary analyses of routinely collected data or existing
research datasets.
• Studies on diabetes research (e.g., risk factors, prognosis, prevention, diagnosis, treatment,
and epidemiology).
• Studies conducted in mainland China or the USA.
• Studies published either in 2010 or 2015, in scientific journals, and with abstracts.
Studies were excluded if they were published in languages other than English or were literature
reviews, editorials, letters, or study protocols.
2.2. Study Search and Selection Strategy
We searched PubMed to identify studies published either in 2010 or 2015, conducted in China or
the USA. Studies were searched up to May 2016 using the search strategy described in supplementary.
Citations of all identified records were downloaded to an EndNote database, and then exported to a
Microsoft Excel spreadsheet by publication year and country. Each of the originally identified records
by publication year and country was assigned a random number from 0 to 1 (generated by Excel). The
records were listed from the smallest to the largest by the assigned random numbers. The first 200
eligible studies from each of the four groups (i.e., 2010 China, 2015 China, 2010 USA, and 2015 USA)
were selected by screening titles and abstracts. If a selected study was not eligible, a successive record
from the group was used to replace it until the total number of included studies was 200 for each of the
four groups. Figure 1 shows the process of the selection of the 800 studies. Figure 1 
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Figure 1. Selection process of relevant studies.
Int. J. Environ. Res. Public Health 2019, 16, 2989 3 of 8
2.3. Data Extraction and Analysis
Data extraction was completed in an Excel sheet (supplementary) using information from titles
and abstracts of the included studies. The extracted data included information such as author, year of
publication, country, language, study design, participants/subjects, relevance, risk factors investigated,
and type of interventions.
Pilot data extraction of the first 20 studies was conducted independently by two reviewers (HF
and FS). The results were compared and any discrepancies discussed between the reviewers. The
data extraction sheet was revised accordingly based on the results of the pilot. The remaining studies
were extracted by two independent researchers (GJ and HF) and checked by two other independent
researchers (FS and SB). Any disagreements were resolved through discussion.
The main characteristics of the included studies are summarized in Table 1. The results were
stratified by country. We compared the descriptive summary statistics for studies published in 2010
and 2015. The included data was processed and analyzed by Epidata 3.1 and SPSS 20.0 (SPSS, Inc.,
Chicago, IL, USA).
Table 1. The main characteristics of included studies.
Countries of Authors
Published in 2010 Published in 2015 All
China USA China USA China USA p
China 200 (100%) 0 (0%) 187 (93.5%) 0 (0%) 387 (96.7%) 0 (0%) 0.000 *
USA 0 (0%) 200 (100%) 0 (0%) 151 (75.5%) 0 (0%) 351 (87.7%)
Multiple 0 (0%) 0 (0%) 13 (6.5%) 49 (24.5%) 13 (3.3%) 49 (12.3%)
Publication language
Chinese 49 (24.5%) 0 (0%) 20 (10%) 0 (0%) 69 (17.3%) 0 (0%) 0.000 *
English 151 (75.5%) 200 (100%) 180 (90%) 200 (100%) 331 (82.7%) 400 (100%)
Data source
Primary 190 (95%) 139 (69.5%) 194 (97%) 164 (82%) 384 (96%) 303 (75.7%) 0.000 *
Secondary 10 (5%) 61 (30.5%) 6 (3%) 36 (18%) 16 (4%) 97 (24.3%)
Design
Case series 13 (6.5%) 5 (2.5%) 1 (0.5%) 3 (1.5%) 14 (3.5%) 8 (2.0%) 0.000 **
Case-control 39 (19.5%) 19 (9.5%) 32 (16%) 21 (10.5%) 71 (17.7%) 40 (10%)
Clinical trial 14 (7%) 25 (12.5%) 11 (5.5%) 33 (16.5%) 25 (6.2%) 58 (14.5%)
Cohort 12 (6%) 53 (26.5%) 23 (11.5%) 51 (25.5%) 35 (8.8%) 104 (26%)
Cross sectional 24 (12%) 37 (18.5%) 29 (14.5%) 30 (15%) 53 (13.3%) 67 (16.7%)
Laboratory-based 98 (49%) 61 (30.5%) 104 (52%) 62 (31%) 202 (50.5%) 123 (30.8%)
Study subjects
Animal 92 (46%) 55 (27.5%) 96 (48%) 55 (27.5%) 188 (47%) 110 (27.5%) 0.000 **
Bio-sample 6 (3%) 5 (2.5%) 8 (4%) 6 (3%) 14 (3.5%) 11 (2.7%)
Care providers 0 (0%) 4 (2%) 0 (0%) 1 (0.5%) 0 (0%) 5 (1.3%)
Patients 86 (43%) 120 (60%) 85 (42.5%) 123 (61.5%) 171 (42.7%) 243 (60.7%)
Population 16 (8%) 12 (6%) 10 (5%) 14 (7%) 26 (6.5%) 26 (6.5%)
Multiple 0 (0%) 3 (1.5%) 1 (0.5%) 1 (0.5%) 1 (0.3%) 4 (1%)
Other 0 (0%) 1 (0.5%) 0 (0%) 0 (0%) 0 (0%) 1 (0.3%)
Type of diabetes
Type 1 and 2 191 (95.5%) 172 (86%) 162 (81%) 171 (85.5%) 353 (88.3%) 343 (85.7%) 0.221 *
Gestational 4 (2%) 4 (2%) 8 (4%) 4 (2%) 12 (3%) 8 (2%)
With other diseases 5 (2.5%) 24 (12%) 30 (15%) 25 (12.5%) 35 (8.7%) 49 (12.3%)
Notes: * p value is based on Pearson’s chi-square test. ** p value is based on Fisher’s exact test.
3. Results
The PubMed search yielded a total of 6642 references for studies published in 2010 and 2015. The
number of studies conducted in China was 705 in 2010 and 1160 in 2015, and the number of studies
conducted in the USA was 2670 in 2010 and 2107 in 2015. Considering time and resource limitations, a
total of 800 studies were included in the analysis. The process of selection of relevant studies is shown
in Figure 1.
3.1. Main Characteristics of Included Studies
None of the included studies in 2010 had authors from multiple countries. For studies published
in 2015, the proportion of studies with authors from multiple countries was 6.5% in China and 24.5% in
the USA. Studies from the USA were all published in English. The proportion of studies published in
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English in China increased over time (75.5% in 2010 versus 90.0% in 2015). Primary studies accounted
for 96% of all included studies from China, and 75.7% from the USA.
Studies from China were more likely to be laboratory-based (50.5% versus 30.8%), less likely
to be clinical trials (6.2% versus 14.5%) or cohort studies (8.8% versus 26.0%), and more likely to be
case-control studies (17.7% versus 10.0%), compared with those conducted in the USA. The proportion
of randomized controlled trials (RCTs) in China remained very low in both 2010 (6%) and 2015 (5%).
Compared to studies from the USA, studies from China, were less likely to include patients as
subjects (42.7% versus 60.7%) and more likely to use animals as subjects (47.0% versus 27.5%). The
majority of the included studies considered type 1 or 2 diabetes (88.3% in China and 85.7% in the USA).
A small proportion of studies considered gestational diabetes (3% in China and 2% in the USA), and
some studies considered diabetes with other diseases (e.g. chronic kidney disease, hypertension, HIV
infection, etc.) (8.7% in China and 12.3% in the USA).
3.2. Relevance of the Included Studies
Table 2 shows the relevance of the included studies. The proportion of studies relevant to
treatments was higher in China (42.3%) than the USA (37.3%). Similar percentages were observed
in both countries for diagnosis (7.7% in both countries) and prognosis (6.0% versus 7.5%). Studies
in China were more likely to be relevant to disease risk factors (22.7%) compared to those in the
USA (14.7%). The percentage of studies relevant to prevention was small, particularly in China (0.7%
versus 3.3%).
Table 2. Relevance evaluated in the included studies.
Relevance of the
Included Studies
Published in 2010 Published in 2015 All
China USA China USA China USA p Value
Consequence 0 (0%) 2 (1%) 0 (0%) 5 (2.5%) 0 (0%) 7 (1.7%) 0.015 **
Diagnosis 19 (9.5%) 15 (7.5%) 12 (6%) 16 (8%) 31 (7.7%) 31 (7.7%) 1.000 *
Disease risk factors 47 (23.5%) 29 (14.5%) 44 (22%) 30 (15%) 91 (22.7%) 59 (14.7%) 0.005 *
Epidemiology 6 (3%) 9 (4.5%) 3 (1.5%) 7 (3.5%) 9 (2.3%) 16 (4%) 0.222 *
Prevention 1 (0.5%) 7 (3.5%) 2 (1%) 6 (3%) 3 (0.7%) 13 (3.3%) 0.020 *
Prognosis 10 (5%) 14 (7%) 14 (7%) 16 (8%) 24 (6%) 30 (7.5%) 0.481 *
Treatment 84 (42%) 79 (39.5%) 85 (42.5%) 70 (35%) 169 (42.3%) 149 (37.3%) 0.170 *
Multiple 2 (1%) 0 (0%) 3 (1.5%) 3 (1.5%) 5 (1.3%) 3 (0.7%) 0.725 **
Other 31 (15.5%) 45 (22.5%) 37 (18.5%) 47 (23.5%) 68 (17%) 92 (23%) 0.042 *
Notes: * p value is based on Pearson’s chi-square test; ** p value is based on Fisher’s exact test. Other: including
pathology, physiology, or diabetes as a risk factor for other diseases, etc.
3.3. Type of Interventions
Table 3 shows the type of interventions investigated. Nearly half of the included studies evaluated
interventions. Pharmacological interventions were evaluated more in China (36.5%) than in the USA
(20.7%). However, studies evaluating disease management interventions were less common in China
(3.3%) than in the USA (13.3%). Of all the included studies, only 0.2% in China evaluated behavioral
interventions, compared with 5.8% in the USA.
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Table 3. Interventions evaluated in the included studies.
Type of Interventions Published in 2010 Published in 2015 all
China USA China USA China USA p
Behavioral or Educational 0 (0%) 12 (6.0%) 1 (0.5%) 11 (5.5%) 1 (0.2%) 23 (5.8%) 0.000 *
Biological 8 (4%) 5 (2.5%) 6 (3%) 7 (3.5%) 14 (3.5%) 12 (3%) 0.842 *
Diagnostic tests 10 (5%) 11 (5.5%) 12 (6%) 11 (5.5%) 22 (5.5%) 22 (5.5%) 1.000 *
Disease management 8 (4%) 34 (17%) 5 (2.5%) 19 (9.5%) 13 (3.3%) 53 (13.3%) 0.000 *
Pharmacological 71 (35.5%) 41 (20.5%) 75 (37.5%) 42 (21%) 146 (36.5%) 83 (20.7%) 0.000 *
Radiological 1 (0.5%) 0 (0%) 0 (0%) 0 (0%) 1 (0.3%) 0 (0%) 1.000 **
Surgical 4 (2%) 10 (5%) 5 (2.5%) 3 (1.5%) 9 (2.3%) 13 (3.3%) 0.518 *
Multiple 3 (1.5%) 1 (0.5%) 0 (0%) 2 (1%) 3 (0.7%) 3 (0.7%) 1.000 **
NA 95 (47.5%) 83 (41.5%) 93 (46.5%) 101 (50.5%) 188 (47%) 184 (46%) 0.557 *
Other 0 (0%) 3 (1.5%) 3 (1.5%) 4 (2%) 3 (0.7%) 7 (1.7%) 0.341 *
Notes: * p value is based on Pearson’s chi-square test; ** p value is based on Fisher’s exact test.
4. Discussion
Existing evidence on the comparison of research on diabetes between developing and developed
countries is limited. Diabetes is one of the diseases resulting in high morbidity and mortality in China,
but the quantity of research carried out appears to be disproportionately small given the health and
economic burden of disease. This comparative study of randomly selected studies from the USA and
China highlights the difference in diabetes research between these countries.
The total number of published studies on diabetes from China was lower compared to the USA
(Figure 2). Several underlying factors may contribute to the lower number of diabetes studies in
China. Historically, diabetes has not been a public health priority in developing countries [16]. In
addition, diabetes research conducted in China may remain unpublished or may be published in
national journals that have not been indexed in PubMed. The number of studies on diabetes in China
has significantly increased by nearly 150% (705 in 2010 to 1754 in 2015), while the number of studies
on diabetes from the USA increased only by 18% (2669 in 2010 to 3152 in 2015). This rapid rise in
output between 2010 and 2015 indicates an increase in diabetes research in China, and also represents
increased local activities within the country on the development and implementation of evidence-based
solutions for diabetes.
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Authorship of published research from multiple countries directs the international collaboration in
the diabetes research field. The findings of this study show that international collaboration in diabetes
research was previously limited in China compared with the USA. Our previous study showed that
that research conducted in developed countries tends to beat a lower risk of bias [7]. Given this lo er
bias in developed countries, international research collaborations between developed and developing
countries may encourage capacity building and quality improvement, and equally enhance care for
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patients with diabetes. Large multinational research that crosses cultures and levels of socioeconomic
development might have wider applicability than single-country research [17]. To tackle the rising
global burden of diabetes, more international collaboration between countries should be encouraged.
The current study shows that researchers from the USA were more likely to use secondary data
compared to those in China. Health authorities and researchers worldwide have been collecting large
amounts of primary data for decades. Previously, the utilization of such data has been very limited
due to difficulties in access, scale, and linkages. There are growing efforts to reduce waste in research
by using existing data fully to its capacity, especially in developed countries [18]. Routinely collected
data might have the potential to facilitate research capable of providing answers to important health
questions efficiently and cost-effectively. The key issue is whether such data can be reliably used to
produce high quality research. With data access opening, secondary data should be considered before
conducting any more primary studies [19]. In the past evidence obtained from analyzing secondary
data was scarce. This gap has now been addressed by researchers [20].
The majority of diabetes studies both in the USA and China was laboratory-based research, and
the percentage of laboratory-based research in China was higher than that in the USA (50.5% versus
30.8%). Compared with studies in the USA, studies in China were more likely to use animals as study
subjects (47.0% versus 27.5%) and less likely to directly involve patients (42.7% versus 60.7%). In
addition, studies in China was more likely to focus on disease risk factors than those in the USA (22.7%
versus 14.7%).
The number of studies on treatment for diabetes was higher in China than in the USA (42.3%
versus 37.3%). There were a small proportion of studies directly relevant to the prevention of diabetes
in both countries (0.7% in China versus 3.3% in the USA). Regarding the type of interventions, studies
in China were more likely to focus on pharmacological treatments (36.5% versus 20.7%) and less
likely to study disease management interventions (3.3% versus 13.3%) or behavioral or educational
interventions (0.2% versus 5.8%), compared with studies in the USA. RCTs provide the most valid
evidence on the effects of clinical and public health interventions. However, the proportion of RCTs in
China was much lower than that of the USA (5.5% versus 12.5%).
The type of studies on diabetes reflects research priorities perceived by funding bodies and
researchers. Although laboratory-based and animal studies are required to understand the pathological
process and biological mechanisms of diabetes, translation of findings from such studies to clinical
applications usually takes decades, and even highly promising basic research often fails to be clinically
useful [21]. Patient-based clinical studies may generate findings that are more relevant to current
health care practice for the prevention and management of diabetes. Therefore, balanced allocation
of research funding on different types of research studies is required. Compared with studies in the
USA, studies in China were more likely to be laboratory-based or animal studies, and less likely to be
patient-based clinical trials. The Healthy China 2030 plan, issued by the Chinese government in 2016,
lists of its key objectives as increasing the population’s life expectancy from 76 to 79 years by 2030 [22].
To achieve this objective, patient- and community-based studies are required to provide evidence on
the prevention and treatment of diseases. Particularly, the number of RCTs and studies on disease
management interventions in China needs to increase to provide research evidence that can have an
immediate impact on patient management and population health. Moreover, collaboration between
researchers in more and less developed countries should be promoted to overcome problems caused
by limited research capacity in less developed countries.
A limitation of the present study is that we included only research published in 2010 and 2015,
and further studies are required to monitor any changes in the main characteristics of research on
diabetes. Furthermore, the present study revealed considerable differences in research on diabetes
between China and the USA. Further studies are required to investigate possible reasons for and causes
of the observed differences.
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5. Conclusions
The number of studies on diabetes in China is rapidly increasing, but is still lower compared to
the USA. Studies of diabetes in China were more likely to be basic or animal studies, and less likely to
be patient-based clinical trials. For the control and management of diabetes, more resources should be
allocated to patient-based clinical studies. Collaboration between researchers in developed and less
developed countries should be encouraged.
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